INC Research Holdings (INCR) Shares are Down -1.18%

INC Research Holdings (INCR) has risen sharply, recording gains of 9.44% in the past 4 weeks. However, the stock has corrected -1.18% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.32% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.3% and the 50-Day Moving Average is 8.77%. INC Research Holdings (NASDAQ:INCR): stock turned positive on Friday. Though the stock opened at $46.28, the bulls momentum made the stock top out at $46.295 level for the day. The stock recorded a low of $44.86 and closed the trading day at $45.1, in the green by 0.20%. The total traded volume for the day was 741,724. The stock had closed at $45.01 in the previous days trading.


The company Insiders own 1.7% of INC Research Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -35.59% . Institutional Investors own 88.42% of INC Research Holdings shares. During last six month period, the net percent change held by insiders has seen a change of -35.59%. Also, Equity Analysts at the Brokerage Firm, Goldman Sachs, maintains their rating on the shares of INC Research Holdings (NASDAQ:INCR). Goldman Sachs has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $62 per share from a prior target of $60. The rating by the firm was issued on August 12, 2016.

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.